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Abstract
Background
Somatostatin (SST) has anti-proliferative and pro-apoptotic effects. Our aims were to ana-
lyze and compare the SST expression during normal aging and colorectal carcinogenesis
at mRNA and protein levels. Furthermore, we tested the methylation status of SST in biopsy
samples, and the cell growth inhibitory effect of the SST analogue octreotide in human colo-
rectal adenocarcinoma cell line.
Methods
Colonic samples were collected from healthy children (n1 = 6), healthy adults (n2 = 41) and
colorectal cancer patients (CRCs) (n3 = 34) for SSTmRNA expression analysis, using
HGU133 Plus2.0 microarrays. Results were validated both on original (n1 = 6; n2 = 6; n3 = 6)
and independent samples ((n1 = 6; n2 = 6; n3 = 6) by real-time PCR. SST expressing
cells were detected by immunohistochemistry on colonic biopsy samples (n1 = 14; n2 = 20;
n3 = 23). The effect of octreotide on cell growth was tested on Caco-2 cell line. SST methyla-
tion percentage in biopsy samples (n1 = 5; n2 = 5; n3 = 9) was defined using methylation-
sensitive restriction enzyme digestion.
Results
In case of normal aging SST mRNA expression did not alter, but decreased in cancer
(p<0.05). The ratio of SST immunoreactive cells was significantly higher in children
(0.70%±0.79%) compared to CRC (0%±0%) (p<0.05). Octreotide significantly increased
the proportion of apoptotic Caco-2 cells. SST showed significantly higher methylation level
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in tumor samples (30.2%±11.6%) compared to healthy young individuals (3.5%±1.9%)
(p<0.05).
Conclusions
In cancerous colonic mucosa the reduced SST production may contribute to the uncon-
trolled cell proliferation. Our observation that in colon cancer cells octreotide significantly
enhanced cell death and attenuated cell proliferation suggests that SST may act as a regu-
lator of epithelial cell kinetics. The inhibition of SST expression in CRC can be epigenetically
regulated by promoter hypermethylation.
Introduction
Somatostatin (SST), a regulatory-inhibitory peptide, has remarkable effect on gastrointestinal
function. It suppresses gastrointestinal motility and gall bladder contraction, inhibits gut exo-
crine secretion, regulates the intestinal nutrient absorption and blood flow, and decreases epi-
thelial proliferation [1–5]. In addition SST inhibits hormone release (e.g. GH, TSH, insulin, gut
hormones), serves as neurotransmitter and neuromodulator, and contributes to water balance
[1,4,6]. Beyond these physiological endocrine and paracrine/autocrine effects, SST can directly
inhibit cell proliferation and induce apoptosis via somatostatin receptor (SSTR) signaling [4,7].
Therefore, reduced somatostatin levels, which we found in a pilot study might have relevance
in gastrointestinal tumorigenesis including colorectal cancer which is one of the leading causes
of cancer-related death [8].
Somatostatin is mainly produced in the central and peripheral nervous system, in the endo-
crine pancreas and in the gut; furthermore minor SST secretion also has been proven in the
thyroid, adrenals, submandibular glands, kidneys, prostate, placenta and the cells of the im-
mune system. SST is synthesized from a large precursor molecule called preprosomatostatin
(preproSST) that is processed enzymatically to mature products. Two bioactive peptide prod-
ucts of SST encoding gene are known, SST-14 and SST-28 [1]. SST-28 is synthesized in the in-
testinal mucosa, which is the largest peripheral source of the peptide and the major SST
producing cells in the gastrointestinal tract are mucosal δ-cells in the intestinal epithelium, D-
cells in the gastric antrum and pancreas, and intrinsic neurons in the myenteric and submuco-
sal plexuses along the digestive tract [3]. Somatostatin release can be stimulated and inhibited
by several hormones, neuropeptides, neurotransmitters, cytokines, growth factors and nutri-
ents. For example, growth hormone-releasing hormone (GHRH), corticotropin-releasing hor-
mone (CRH), neurotensin, bombesin, IL-1, IL-6 and TNF-α can stimulate the SST secretion in
several tissues. On the other hand, the γ aminobutiric acid (GABA), opiates, TGF-β and leptin
are potential inhibitors of SST release. Nutrients have tissue-specific effect on SST production,
and gut SST secretion is triggered by luminal but not circulating nutrients [1].
The five known somatostatin receptors (SSTR1, SSTR2 /SSTR2A, SSTR2B/, SSTR3, SSTR4,
SSTR5) encoded by five human genes are typical G-protein-coupled receptors (GPCR) with
seven α-helical transmembrane segments. Upon binding of SST to its receptors, several cellular
functions are modulated through multiple G-protein dependent signaling pathways. Different
signaling pathways are activated depending on the receptor subtype and tissue localization. All
SSTR subtypes inhibit adenylate cyclase and cAMP production, regulate protein phosphatases
and activate G-protein regulated inward rectifier K+ channel (GIRK) family upon ligand bind-
ing [1,2,5,9,10].
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The manifestation of antiproliferative and pro-apoptotic effects of SST on normal and tu-
morous cells depends on the type of ligand binding SSTR. SST and its analogs have indirect
effects on cell growth by inhibiting the angiogenesis, modulating the immune system and
inhibiting growth factors (e.g. IGF-1) and trophic hormones release. Furthermore, it can
induce apoptosis, inhibit the cell cycle and modulate the impact of growth factors directly
[11–14].
In our previous studies we have summarized the macroscopic, microscopic and molecular
changes affecting the gastrointestinal tract, particular the large bowel during normal aging
[15–17]. We have demonstrated that healthy juvenile colonic epithelium and colorectal cancer
can be characterized with increased cell proliferation and decreased apoptosis compared to the
healthy adult colonic mucosa. However, while cell proliferation is strictly regulated and well-
balanced in children, it become uncontrolled in CRC. We have also revealed that alterations in
mRNA expression during normal aging and colorectal carcinogenesis can be related to in-
creased, but differently regulated cell growth [18]. The purpose of this study was to analyze
local somatostatin production in human colonic epithelium during normal aging and colorec-
tal carcinogenesis, both at mRNA and protein expression levels. We also investigated the effects
of somatostatin analogue octreotide on human colorectal adenocarcinoma cell line (Caco-2).
Since promoter hypermethylation can epigenetically alter gene transcription both during aging
and carcinogenesis, we tested the methylation status of SST gene.
Materials and Methods
Patients and samples
After informed consent, colorectal biopsy samples were taken during routine endoscopic inter-
vention at the 2nd Department of Internal Medicine and at the 1st Department of Paediatrics,
Semmelweis University, Budapest, Hungary. Written informed consent was obtained in ad-
vance from all adult participants and from the next of kin, caretakers, or guardians on the be-
half of the minors/children approved by the ethics committees. Altogether, 81 biopsy samples
were analyzed in microarray analysis (6 healthy children, 41 healthy adults and 34 CRCs from
adults) and 36 biopsy samples were involved in real-time PCR validation (12 healthy children,
12 healthy adults and 12 CRCs from adults). Fifty-seven tissue samples were analyzed by
immunohistochemistry (14 healthy children, 20 healthy adults and 23 CRCs from adults) and
15 colonic biopsies were investigated using methylation-sensitive restriction enzyme methyla-
tion array analysis (5 healthy children, 5 healthy adults and 9 CRCs from adults). Seventy-five
microarrays (containing the adult samples) had been hybridized earlier; their data files were
used in previously published studies using different comparisons [19–21] and are available in
the Gene Expression Omnibus database (series accession number: GSE10714 and GSE37364).
The datasets of the newly hybridized 6 microarrays are registered on the GSE37267 serial ac-
cession number. Control children were referred to the outpatient clinic with constipation, rec-
tal bleeding or chronic abdominal pain. Ileocolonoscopy was part of their diagnostic procedure
(to exclude organic disease) and the biopsy specimens showed normal macroscopic appearance
and histology. Every specimen was verified by histopathologists. For mRNA studies (microar-
ray analysis, Taqman RT-PCR) and methylation array analysis, colonic samples were stored in
RNALater Reagent (Qiagen Inc, Germantown, US) at −80°C before nucleic acid extraction. Co-
lorectal biopsy samples were routinely fixed in formaldehyde and embedded in paraffin wax
for immunohistochemistry experiments.
Ethical approvals (Nr.: 69/2008 and 202/2009) for this study were issued by the Regional
and Institutional Committee of Science and Research Ethics of Semmelweis University
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(Budapest, Hungary). Detailed clinicopathological specification of the patient samples are sum-
marized in Table 1.
mRNA expression microarray analysis
According to the manufacturer’s instructions, total RNA was extracted using RNeasy Mini Kit
(Qiagen Inc., Germantown, USA). The quantity of isolated RNA was characterized by measur-
ing absorbance (NanoDrop ND-1000 Spectrophotometer, NanoDrop Technologies, Inc., Wil-
mington, USA) and the quality of isolated RNA was tested with capillary gel electrophoresis
(2100 Bioanalyzer and RNA 6000 Pico Kit /Agilent Inc., Santa Clara, CA, USA/). According to
the Affymetrix description, biotinylated cRNA probes were synthesized from 1 to 8 μg total
RNA with RIN (RNA Integrity Number) between 7–10 and fragmented using the One-Cycle
Target Labeling and Control Kit (http://www.affymetrix.com/support/downloads/manuals/
expression_s2_manual.pdf ). Ten micrograms of each fragmented cRNA sample was hybrid-
ized into HGU133 Plus2.0 array (Affymetrix, Santa Clara, CA, USA) at 45°C for 16 h. The
Table 1. Subgroups of patients involved in Affymetrix microarray analysis, PCR validation,
immunohistochemistry, and methylation array analysis with the number of samples and mean age
values.
Number of patients participating in the study
Affymetrix microarray analysis
Group Number of samples (female/male) Mean age ± SD (years)
Children (Ch) 6 (2/4) 12.2 ± 5.3
Healthy adults (N) 41 (26/15) 53.0 ± 15.9
CRCs from adults (CRC) 34 (19/15) 68.5 ± 10.3
Total patient number 81 (47/34)
Taqman RT-PCR validation
Group Number of original samples (female/male) Mean age ± SD (years)
Children (Ch) 6 (2/4) 12.2 ± 5.3
Healthy adults (N) 6 (3/3) 57.7 ± 18.9
CRCs from adults (CRC) 6 (4/2) 69.0 ± 7.0
Total patient number 18 (9/9)
Group Number of independent samples (female/male) Mean age ± SD (years)
Children (Ch) 6 (3/3) 5.5 ± 3.4
Healthy adults (N) 6 (3/3) 53.0 ± 16.9
CRCs from adults (CRC) 6 (1/5) 64.3 ± 10.8
Total patient number 18 (7/11)
Immunohistochemistry
Group Number of samples (female/male) Mean age ± SD (years)
Children (Ch) 14 (7/7) 9.86 ± 6.0
Healthy adults (N) 20 (11/9) 58.5 ± 14.0
CRCs from adults (CRC) 23 (13/10) 67.3 ± 10.5
Total patient number 57 (31/26)
Methylation array analysis
Group Number of samples (female/male) Mean age ± SD (years)
Children (Ch) 5 (2/3) 7.2 ± 6.3
Healthy adults (N) 5 (2/3) 56.8 ± 18.7
CRCs from adults (CRC) 9 (5/4) 65.8 ± 9.1
Total patient number 19 (9/10)
doi:10.1371/journal.pone.0118332.t001
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microarrays were washed using Fluidics Station 450 device, and stained with antibody amplifi-
cation staining method according to the manufacturer’s instructions. Fluorescent signals were
detected by GeneChip Scanner 3000 (Affymetrix).
TaqMan real-time polymerase chain reaction (RT-PCR) validation
TaqMan polymerase chain reaction was used to measure mRNA expression of SST encoding
gene on original (6 histologically intact children, 6 histologically intact adult and 6 adult CRC
samples) and independent sets of samples (6 histologically intact children, 6 histologically in-
tact adult, 6 adult CRC samples). 18S ribosomal RNA (Hs03928990_g1) and GAPDH
(Hs03929097_g1) were used as reference gene.
Total RNA extraction, quality and quantity controls were performed as described earlier.
Using the High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor, 1μg of total
RNA per sample was reverse transcribed (Life Technologies, Carlsbad, CA, USA). The quality
of cDNA was checked by SDHA real-time PCR (F. Hoffmann-La Roche Ltd., Basel, Switzer-
land). Then 16.7 ng cDNA template per sample was used for SST (Hs00174949_m1) mRNA
expression analysis with TaqMan Gene Expression Master Mix (Life Technologies). The mea-
surements were carried out on LightCycler 480 (Roche) with Mono Color Hydrolysis Probe /
UPL Probe detection format. After denaturation at 95°C for 10 min, 40 PCR cycles were carried
out (amplification at 95°C for 15 sec, and at 60°C for 1 min).
Immunohistochemistry for the detection of somatostatin producing cells
Cores of 2 mm diameter were collected from selected areas of formalin-fixed, paraffin-embedded
tissue blocks prepared from 20 normal colon samples and 23 colorectal cancers of adult patients
and inserted into tissue microarray (TMA) recipient blocks. Furthermore, 14 histologically intact
colonic biopsy samples from children were also examined on protein level. 5 μm thick tissue sec-
tions were cut from TMA blocks and from biopsy samples, and were immunostained. Endoge-
nous peroxidase blocking (0.5% hydrogen peroxide and methanol mixture, 30 min, room
temperature) and antigen retrieval (Target Retrieval Solution, Dako, Glostrup, Denmark, code:
S1699, in pH 6 buffer, performed in a microwave at 900W for 10 min and at 370W for 40 min)
were carried out on dewaxed samples. Non-specific blocking with 1% bovine serum albumin was
applied. Immunohistochemical detection of somatostatin was carried out in a humidified cham-
ber using rabbit anti-human polyclonal antibody (1:50 dilution, overnight, Thermo Scientific, Cal-
ifornia, USA, code: RB-038-A). EnVision + HRP system (Labeled Polymer Anti-Rabbit, 40 min,
Dako, code: K4003) and diaminobenzidine—hydrogen peroxidase—chromogen—substrate sys-
tem (Cytomation Liquid DAB + Substrate Chromogen System, 10 min, Dako, code: K3468) were
used for signal conversion. Finally, hematoxylin co-staining was carried out.
Counting of somatostatin producing cells on digital slides
Stained biopsy samples and tissue microarray (TMA) slides were digitalized with a high resolu-
tion digital scanner (Pannoramic Scan, 3DHISTECH Ltd. Budapest, Hungary) using multilayer
fluorescent scanning with a high numeric aperture (0.8) x20 objective lens and a high dynamic
range AxioCamMrm Rev.3 black-and-white camera connected to the scanner. Digital slides
were accessed through a computer monitor and analyzed using the Pannoramic Viewer soft-
ware (version 1.11.43.0). The Marker Counter software module resulting in permanent annota-
tions on the counted cells was used to estimate the relative ratio SST producing and other
epithelial cells. Epithelial SST positivity appeared all as strong brown cytoplasmic labeling in
the slides. Depending on sample size, 500–1000 epithelial cells were counted in longitudinal
well-oriented crypts.
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Treatment of Caco-2 cells with somatostatin analogue octreotide and
measurement of Sub-G1 population using flow cytometry
Cell culture and treatment. Cell culture experiment was maintained in a specific pathogen cell
culture laboratory. Caco-2 human epithelial adenocarcinoma cell line was obtained from
DSMZ (Braunschweig, Germany; Cat. No. ACC-169). Cells were grown to confluence in MEM
medium (Sigma-Aldrich, St. Louis, USA; Cat. No. M 2279), supplemented with 20% Fetal
Bovine Serum (Sigma-Aldrich, St. Louis, USA; Cat. No. F 24429) and 160 μg/ml gentamycin
(Sandoz GmbH, Schaftenau, Austria). Subsequently, 70.000 Caco-2 cells were settled for l
well to a 24-well treatment plate in MEM supplemented with gentamycin and FCS. After
24 hours medium was changed: MEM was added with gentamycin and with 0.1, 1.0, 2.5, 5.0
and 10.0 nmol/l of octreotide (Sandoz GmbH) without FCS. Measurement was performed in
triplicates for each concentration. After 24, 48 and 72 hour treatment the cells were harvested,
two times washed in 0.5 ml sterile PBS and finally resuspended in 1.0 ml of ice cold 70% etha-
nol and stored at -20°C.
Flow cytometry and Sub-G1 population detection. Samples were centrifuged for 3 min at
1300 rpm, then the cells were resuspended in 300 μ1 of extraction buffer and 3 μl of RNAse
(RNase A/T1 Mix, Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania) was added. After
15 min incubation at room temperature, 3 μl of propidium jodide (Sigma-Aldrich, St. Louis,
USA; Cat. No. 81845) was added. The FACS measurement was performed on Becton Dickin-
son Immunocytometry Systems (Mountain View, California, USA, Serial No. 81313).
Methylation-sensitive restriction enzyme methylation array analysis
Biopsy samples were homogenized in 2% sodium dodecyl sulphate for DNA extraction, and
then incubated in Proteinase K digestion buffer (4 mg/mL) at 60°C for 16 hours. DNA extraction
was performed with High Pure PCR Template Preparation Kit (Roche Applied Science, Penz-
berg, Germany) as instructed by the manufacturer. DNA was eluted in 2x100 μl RNase- and
DNase-free water and stored at -20°C. DNAmethylation profiles were examined using the Epi-
Tect Methyl qPCR Array System (Qiagen, Hilden, Germany). The isolated DNA was incubated
with either DNAmethylation dependent or DNA sensitive restriction enzymes for 16 h at 37°C,
then incubated at 65°C to halt methylase activity. Each 120 μL reaction contained 500 ng of ge-
nomic DNA. Following enzyme digestion, samples were analyzed by fluorescence-based, quanti-
tative PCR using LightCycler 480 (Roche Diagnostics, Basel, Switzerland). PCR was performed
at the following conditions: 95°C for 10 min, 40 cycles (97°C for 15 sec; and 72°C for 1 min—
with real-time data acquisition). To ensure amplification of desired products, melting curve
analysis was performed following the real-time PCR reaction. The melting curve data acquisition
range was 65°–95°C, holding for 1 s at increments of 0.04°C for PCR product detection.
Statistical evaluation
For mRNA expression profiling, the Affymetrix expression arrays were primarily pre-pro-
cessed by GCRMA background correction method with quantile normalization and median
polish summarization. The expression of SST gene among different sample groups was ana-
lyzed by ANOVA and post-test Tukey HSD. The datasets are available in the Gene Expression
Omnibus databank (http://www.ncbi.nlm.nih.gov/geo/), series accession numbers: GSE10714,
GSE37364 and GSE37267.
For real-time PCR validation of SST expression 12 samples were analyzed in the following
groups: children, healthy/normal adults and adult CRCs. For normalization, 18S ribosomal
RNA was used as housekeeping internal control and dCT values were represented on boxplots.
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Hence data was normal distributed for statistical analysis ANOVA test and Tukey HSD post-
test were applied in order to determine significance. The following criteria were used: Fold
change0.5 or Fold change2 and p-value<0.05.
For statistical analysis of SST immunostaining results the ANOVA test and Tukey HSD
post-test were applied. In both methods significance criteria was p<0.05.
Mann-Whitney test was used to compare the proportion of Caco-2 cells in different cell
cycle stages (Sub-G1, G1, S, G2 and M) of octreotide-treated groups and in the control group.
p<0.05 was considered to be statistically significant.
The results of methylation array analysis were evaluated by ANOVA and Tukey HSD post-
test to determine and compare the proportions of SST promoter methylation in the three
sample groups.
For statistical analysis R 3.1.0 statistical environment was applied. Boxplots represents me-
dian and standard deviation data with outliers.
Results
Somatostatin expression alterations in hyperproliferative states of the
colon
Somatostatin mRNA expression levels in colorectal biopsy samples from healthy juvenile, adult
and colorectal cancer were detected using 213921_at Affymetrix probeset ID (http://www.
affymetrix.com/analysis/index.affx). mRNA expression of SST did not alter during normal
aging as compared healthy juvenile (Ch) and adult (N) samples, however, gene expression sig-
nificantly decreased in colorectal cancer (CRC) (p<0.05) compared to normal adult (N) sam-
ples (Fig. 1).
Real-time PCR validation on the original, the independent and the combined sets of samples
verified the significantly reduced SST expression in CRC (p<0.05) (Fig. 2), and increased SST
production in healthy samples, regardless of age. Immunohistochemical analysis confirmed the
nearly absent somatostatin production in colorectal carcinoma samples as compared to young
and adult healthy colonic mucosa on protein level (p<0.05) (Fig. 3, 4).
The anti-proliferative effects of somatostatin analogue on colorectal
cancer cells
Somatostatin analogue octreotide was added to colorectal adenocarcinoma cells (Caco-2) in
different concentrations. Significantly increased DNA fragmentation (Sub-G1 population) was
measured by flow cytometry after 48 hours compared to the control cells, in a concentration-
dependent manner. In cases of somatostatin analogue treatment at higher concentrations than
0.1 nmol/l, the proportion of apoptotic Sub-G1 fractions was significantly higher (p<0.05)
than it was in the control group, while the proportion of cells in other cell cycle phases (G1, S,
G2, M) was significantly lower. The highest apoptotic fraction (Sub-G1) and the lowest G1, S,
G2, M population were measured at 5.0 nmol/l octreotide concentration. The flow cytometry
results are summarized in Table 2, Table 3 and Fig. 5.
SST promoter DNAmethylation alterations in hyperproliferative states of
the colon
Promoter methylation of somatostatin gene increased during normal aging and carcinogenesis.
The lowest SST promoter methylation was found in juvenile colonic epithelium (3.5%±1.9%)
which can be characterized by controlled, increased cell proliferation. However, in colorectal
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cancer wherein increased cell growth is dysregulated, SSTmethylation was significantly higher
(30.2%±11.6%) (p<0.05). The highest methylation status was detected in CRC (Fig. 6).
Discussion
Colorectal cancer is one of the most frequent malignant tumors with poor outcome in ad-
vanced cases. Its incidence is low under the age of 50, however, it increases rapidly in older age
groups. In developed countries the median age at diagnosis is about 70 years [8] and in the ma-
jority of CRC cases is diagnosed over the age of 65 [22]. Therefore, age can be considered as a
dominant risk factor for colorectal carcinogenesis [23]. Earlier we demonstrated that elevated
cell proliferation is a common feature of colorectal epithelium both in infancy and in cancer
with the significant difference in the control of cell proliferation in cancer [18]. In this study we
demonstrated both at mRNA and protein levels that somatostatin expression does not differ
significantly in elderly healthy colonic epithelium compared to juvenile samples, however, it is
nearly absent in colorectal cancer. The promoter region of SST gene was found to be hyper-
methylated in CRC biopsies, which could be partly reversed by demethylation in cancer cell
lines. Since treatment with the somatostatin analogue octreotide resulted in reduced cell prolif-
eration and elevated apoptosis in a human colorectal adenocarcinoma cell line, our results sug-
gested that the lack of local SST production may contribute to elevated and uncontrolled cell
proliferation in CRC.
Gastrointestinal (GI) hormones (e.g. somatostatin, cholecystokinin (CCK), gastrin, bombe-
sin (BBS)/gastrin-releasing peptide (GRP), neurotensin (NT), peptide YY (PYY), glucagon-like
peptide 2 (GLP-2)) are secreted by endocrine cells, which are located in the intestinal mucosa
Fig 1. mRNA expression of SST—Microarray analysis.mRNA expression microarray analysis of
somatostatin (SST) gene in microscopically normal colonic biopsy samples from children (Ch) and adults (N)
and in colorectal cancer biopsy specimen (CRCs). Red dots are the normalized mRNA expression values,
boxplots represent the median and standard deviation. SST expression significantly decreased in CRC.
doi:10.1371/journal.pone.0118332.g001
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and in the pancreas. These chemical messengers regulate intestinal and pancreatic secretion,
digestion, absorption, motility and cell proliferation. Somatostatin is a regulatory-inhibitory
peptide, which may be considered as a universal switch-off hormone and in addition it can in-
hibit cell growth in normal and neoplastic tissues. SST has endocrine and paracrine/autocrine
Fig 3. Immunohistochemistry for the detection of SST producing cells. Detection of SST producing cells
(brown cytoplasm) during normal aging and in colorectal cancer (CRC). Images were taken with digital
microscope: normal child tissue (Ch) (80-fold magnification), normal adult tissue (N) (55-fold magnification)
and carcinoma (CRC) in adult (20-fold magnification). Only very low SST protein level could be detected in
CRC samples.
doi:10.1371/journal.pone.0118332.g003
Fig 2. mRNA expression of SST—RT-PCR validation. Validation of mRNA expression changes of
somatostatin (SST) gene in histological normal colonic biopsy samples from children (Ch) and adults (N) and in
colorectal cancer biopsy specimen (CRCs) using real-time polymerase chain reaction (RT-PCR) on combined
sample sets. Red dots are the normalized RT-PCR expression values, boxplots represent the median and
standard deviation. RT-PCR analysis verified the significantly decreased SST expression in CRC.
doi:10.1371/journal.pone.0118332.g002
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effects, and can bind to its cell surface G protein-coupled receptors (SSTR1-5) initiating signal
transduction pathways [24].
In this study we have found that the proportion of somatostatin producing cells is less than
1% in histologically normal young and adult colonic epithelium, and significantly reduced in
tumorous samples. Previous immunohistochemical studies have demonstrated dual localiza-
tion of somatostatin being both in endocrine D-cells and nerves in the large intestine [25]. Fur-
thermore, Parsons et al. have also found relative low number of SST positive cells in the colonic
epithelium [26]. In our workgroup Galamb et al. earlier identified genes (e.g. AMN, PTGDR)
Table 2. Distribution of Caco-2 cells in different stages of the cell cycle (average ± standard deviation), in the control and in the octreotide-
treated groups.
Octreotide concentration (nmol/l) Sub-G1 (%) G1 (%) S (%) G2 (%) M (%)
0.0 45.9 ± 5.2 32.2 ± 4.1 2.8 ± 1.5 13.0 ± 2.9 3.8 ± 0.4
0.1 46.1 ± 2.5 28.6 ± 0.7 2.7 ± 0.4 14.2 ± 2.2 5.7 ± 1.4
1.0 70.6 ± 6.4 11.9 ± 2.8 3.9 ± 2.7 7.3 ± 0.5 4.4 ± 1.1
2.5 89.2 ± 0.7 4.3 ± 0.8 1.2 ± 0.2 3.1 ± 1.2 1.5 ± 0.2
5.0 93.0 ± 1.7 3.9 ± 1.1 0.8 ± 0.4 1.5 ± 0.4 0.5 ± 0.2
10.0 89.5 ± 2.0 4.7 ± 0.8 1.1 ± 0.3 3.1 ± 0.5 0.5 ± 0.1
doi:10.1371/journal.pone.0118332.t002
Fig 4. Epithelial production of SST—Immunohistochemistry.Detection of somatostatin (SST) producing
cells in the human normal colonic epithelium from children (Ch) and from adults (N) and in colorectal cancers
(CRCs). Red dots are the ratio of the SST producing cells compared to the total epithelial cell count (%);
boxplots represent the median and standard deviation of the data. SST production significantly decreased in
CRC.
doi:10.1371/journal.pone.0118332.g004
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with decreasing expression during colorectal tumorigenesis [20,27]. Similarly to these markers,
significantly decreased SST production may also contribute to colorectal cancer formation.
Due to the effects of SST on the GI tract, SST analogues can be applied effectively in non-
neoplastic intestinal disorders such as acute variceal bleeding, pancreatic fistula, dumping syn-
drome, or in some cases of chronic diarrhea and intestinal pseudoobstruction [28].
Application of SST analogues is widespread regarding the diagnosis and therapy of neuro-
endocrine tumors [29–31]. Diagnosis of these tumors can be difficult and time consuming,
that can worsen the chance of effective therapeutic intervention [30]. Radiolabelled somatostat-
in analogues can evince the localization of primary and metastatic tumors expressing somato-
statin receptors that can not be detected with conventional imaging techniques due to their
small size [32]. Furthermore, somatostatin and its derivates have several positive effects in the
treatment of neuroendocrine neoplasms. The inhibition of hormonal hypersecretion can pro-
vide symptomatic relief and tumor shrinkage [7]. SST analogues can inhibit the production of
GH and IGF, promoting factors of cancer growth [33]. They can inhibit angiogenesis [34,35],
may play an immunemodulatory role [36,37], and can cause cell cycle arrest and induce
Fig 5. Caco-2 cell culture treatment with somatostatin analogue octreotide. Percentage of cells in
control and octreotide-treated groups with average and standard deviation values. Blue columns represent
the cells in Sub-G1 phase and the proportions of cells in G1+S+G2+M phase are illustrated by red columns.
At higher concentrations than 0.1 nmol/l of added octreotide, the proportion of apoptotic Sub-G1 fraction was
significantly higher (p<0.05) than in the control group, while the proportion of cells in other cell cycle phases
(G1+S+G2+M) was significantly lower. The highest apoptotic fraction (Sub-G1) and the lowest (G1+S+G2
+M) population were measured at 5.0 nmol/l octreotide concentration.
doi:10.1371/journal.pone.0118332.g005
Table 3. P-values of Mann-Whitney rank correlation analysis.
Octreotide concentration (nmol/l) Sub-G1 G1 S G2 M
0.0 vs. 0.1 0.82 0.3827 0.8273 0.5127 0.0495
0.0 vs. 1.0 0.0495 0.0495 0.8274 0.0495 0.3827
0.0 vs. 2.5 0.0495 0.0495 0.0495 0.0495 0.0495
0.0 vs. 5.0 0.0495 0.0495 0.0495 0.0495 0.0495
0.0 vs. 10.0 0.0495 0.0495 0.0495 0.0495 0.0495
The distribution of Caco-2 cells in different cell cycle stages was correlated with the control group. The signiﬁcant different p-values (p<0.05) are marked
in bold.
doi:10.1371/journal.pone.0118332.t003
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apoptosis via somatostatin receptors [11,14]. SST analogues can be safer drugs for long-term
use than cytotoxic chemotherapies, because they have fewer and milder side effects like gastro-
intestinal complaints, cholelithiasis and effects on glucose metabolism [30].
SST analogue scintigraphy can be applied for diagnosing immune-mediated disorders (e.g.
lymphomas, granulomatous disease or rheumatoid arthritis) [38–41] and non-neuroendocrine
tumors, as well [42]. There are several cell culture experiments, animal models and clinical
studies investigating the positive effects of SST analogues in malignant tumors including lym-
phomas, breast cancer and prostate cancer [43–47].
In one clinical study the effect of octreotide was investigated in chemotherapy-refractory
patients with gastric cancer. Significant improvement in survival was observed in the
treated group, compared to the best-supportive care group [48]. The positive impact of SST
analogue therapy on hepatocellular carcinoma (HCC) is not clear. In same cases octreotide ad-
ministration improved the median survival compared untreated patients [49,50], but subse-
quent study in larger population did not show survival benefit for advanced HCC patients
treated with long-acting octreotide compared with placebo [51]. In patients with ductal adeno-
carcinoma of the pancreas, tamoxifen treatment combined with octreotide increased the medi-
an survival times as compared untreated patients [52]. Summarizing other studies, objective
beneficial effects of treatment with octreotide on tumor progression or survival were not
found, however, in individual cases improvement in quality of life was observed [53].
Following the in vitro and in vivo studies clinical trials began in the 80s focusing on the pos-
sible role of somatostatin analogues in the treatment of colorectal cancers. Savage et al. exam-
ined the effects of a long-acting somatostatin analogue (SMS 201–995) in a pilot study on
tumor growth in four patients with advanced colorectal cancer, but they did not find any evi-
dence that the somatostatin analogue can alter the tumor growth [54]. In a phase II study,
Fig 6. Promoter methylation of SST (%)—Methylation specific PCR. Evaluation of promoter methylation
of SST gene in normal colorectal biopsy samples from children (Ch) and from adults (N) and in colorectal
cancers (CRCs) using methylation-sensitive restriction enzymemethylation array analysis. Red dots are the
promoter methylation values of SST (%); boxplots represent the median and standard deviation. The
promoter methylation increases during normal aging and carcinogenesis, and the highest methylation rate
was detected in the tumorous samples.
doi:10.1371/journal.pone.0118332.g006
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16 patients with extensive CRC were treated with three daily subcutaneous injections of San-
dostatin. Stable disease for 3–9 months was observed only in four cases, while other patients
showed progressive disease. However, it is noteworthy that no adverse reactions were detected
and most patients experienced temporary subjective improvements with a decrease in pain
[55]. Cascinu et al. analyzed the anti-tumor effects of octreotide on patients with colorectal
cancer refractory to chemotherapy as compared to the best supportive care. Authors concluded
that the somatostatin analogue therapy confers survival benefit in advanced CRC [48]. Octreo-
tide at a dose of 150 micrograms given three times daily subcutaneously was not effective in
patients with asymptomatic, metastatic colorectal carcinoma in a randomized, controlled, dou-
ble-blind, placebo-controlled phase III study [56].
Summarizing these data, preliminary clinical trials have reported disappointing results for
somatostatin analogues in patients with CRC, but suggesting that the use of somatostatin ana-
logues in incurable, end stage gastrointestinal cancers can reduce the unpleasant symptoms
without any major side effects [57].
The diverse results of the studies found in literature may be caused by methodological alter-
ations and clinical differences [58]. Among the five known somatostatin receptors primarily
SSTR2 and SSTR5 mediate the antiproliferative effect of SST and its analogues. Buscail et al.
demonstrated the loss of SSTR2 gene expression in advanced CRC and their respective metas-
tases, which can also explain the inefficacy of somatostatin analogue therapy in some cases
[59].Miller et al. presented low affinity somatostatin receptor in normal and malignant colonic
tissues. The possible explanation for the function of this receptor is that it may be involved in
the locally produced SST regulation, in a paracrine or autocrine way, as opposed to a true endo-
crine mechanism. Therefore, low concentration of circulating somatostatin and its analogues
can be functionally ineffective contrary to high local levels of SST within the colonic epithelium
[60]. Based on these results, the antiproliferative effect of somatostatin analogue therapy in
CRC can be essentially affected by the local epithelial concentration and the circulation half-
life of the drug.
Forty-eight hours after addition of the somatostatin analogue octreotide, the proportion of
apoptotic cells significantly increased, furthermore the proportion of cells in G1, S, G2 and M
phase significantly decreased, in a concentration-dependent manner. Thus the octreotide treat-
ment slowed down the growth of colorectal cancer cells. Previously Dy et al. also concluded
that long-acting somatostatin analogue SMS 201.995 may have direct antitumor effects on
human colon cancer cell lines [61]. Furthermore the results of Colucci et al. provided novel evi-
dences that somatostatin can decrease COX-2 expression and enzyme function via activation
SSTR3 or SSTR5 in human colon cancer cells, and suggests that these effects can contribute sig-
nificantly to the inhibitory action of SST on cell growth [62]. Somatostatin analogues have also
been extensively tested in vitro on other cultured cells derived from human, non-endocrine tu-
mors with regard to their antiproliferative properties. Cell growth inhibition was detected in
colorectal, gastric, pancreatic, breast, cervical, lung and prostatic cancer cell lines following ad-
ministration of SST analogues [63].
DNA promoter methylation is an epigenetic gene silencing mechanism that regulates gene
expression without changing the DNA sequence. Due to promoter hypermethylation tran-
scription factors can not interact with DNA, diminishing gene expression. Many genetic alter-
ations (e.g. point mutations, insertion-deletion mutations) can be associated with colorectal
carcinogenesis, affecting for example APC, KRAS, p53 and SMAD4 genes. However, it has been
shown in recent years that epigenetic changes also play an important role in the development
of CRC [64,65]. In the present study we have demonstrated that promoter methylation of SST
increases during normal aging and colorectal carcinogenesis and the highest methylation status
was found in CRC. SST promoter hypermethylation was revealed in several gastrointestinal
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tumors in the past decade.Mori et al. similarly demonstrated the epigenetic silencing of so-
matostatin in CRC, and this suggests that inactivation of its growth suppression effect can be
important step in colon tumorigenesis [66]. Increased methylation in the SST promoter region,
causing gene silencing, was evinced in human esophageal carcinomas, and it also occurs early
in Barrett-associated esophageal adenocarcinogenesis [67]. SST promoter methylation is a
common event in human gastric cancer as well; it is connected with a decrease in SST protein
and mRNA levels and associated with gastric carcinogens [68,69].
Conclusions
Somatostatin is probably the most important naturally occurring anti-proliferative hormone.
As we are aware, this is the first study to compare somatostatin expression in colorectal epithe-
lium of healthy children and adults to that found in colorectal cancer samples both at mRNA
and protein levels. Our results show that somatostatin production does not alter significantly
during normal aging, but it is nearly absent in CRC. Earlier we observed increased proliferation
and reduced apoptosis both in juvenile colonic epithelium and in CRC as compared to normal
adult samples, but the control of cell growth was lost in CRC [18]. Our current results suggest
that the significantly reduced epithelial somatostatin production may contribute to the acceler-
ated and deregulated cell proliferation in CRC. This was supported by the inhibition of cancer
cell growth along with the induction of apoptosis upon somatostatin analogue treatment. Re-
duced somatostatin levels were associated with promoter hypermethylation of SST gene as a
potential explanation for the missing hormone in CRC. Further investigations are needed to
test somatostatin analogues and demethylating compounds as potential therapeutic agents
against sporadic colorectal cancer.
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